Research

Investigation of galectin-3 levels in diabetic foot ulcers

Abstract

Objective:

It has been shown that galectin-3 (Gal-3) promotes angiogenesis and new vessel formation. Serum Gal-3 is a risk factor for vascular complications in type 2 diabetes. The aim of this study is to compare Gal-3 levels with a range of biochemical parameters.

Method:

A prospective study consisted of individuals as a control group (group 1), patients diagnosed with type 2 diabetes without DFUs (group 2), and patients with type 2 diabetes with a DFU (group 3). Patient levels of endothelin-1 (ET-1), vascular endothelial growth factor-A (VEGF-A), nitric oxide (NO), and Gal-3 were measured.

Results:

In total, 91 patients participated, (28 male, 63 female with a mean age of 55.83±6.35 years) Mean ET-1 (39.0±16.9), NO (17.6±7.6), VEGF-A (33.5±13.4) and Gal-3 (535.1±420.5) levels were significantly higher in group 3 compared with the other two groups (p<0.01).

Furthermore, the Gal-3 level was positively and statistically significantly correlated with C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), ET-1 and NO levels in all groups.

Conclusion:

In our study, the level of Gal-3 was shown to be positively correlated with the VEGF-A level. Hence, Gal-3 can be considered as a defence mechanism against complications of diabetes, thus contributing to wound healing. Gal-3 may play a critical role in DFU formation and progression. Moreover, it could be suggested that Gal-3 may give an indication of prognosis, as it elevates VEGF-A levels and stimulates angiogenesis. Further studies are required to confirm the findings of this study.

References

1 Driver VR, Fabbi M, Lavery LA, Gibbons G. The costs of diabetic foot: The economic case for the limb salvage team. J Vasc Surg 2010; 52(3 Suppl):17S–22S. https://doi.org/10.1016/j.jvs.2010.06.003 Crossref, Medline, Google Scholar
2 Armstrong DG, Cohen K, Courric S et al.. Diabetic foot ulcers and vascular insufficiency: our population has changed, but our methods have not. J Diabetes Sci Technol 2011; 5(6):1591–1595. https://doi.org/10.1177/193229681100500636 Medline Crossref, Medline, Google Scholar
3 Ochieng J, Furtak V, Lukyanov P. Extracellular functions of galectin-3. Glycoconj J 2002; 19(7-9):527–535. https://tinyurl.com/yas45gdf Google Scholar
4 Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochimica et Biophysica Acta (BBA)–General Subjects 2006; 1760(4):616–635. https://doi.org/10.1016/j.bbagen.2005.12.020 Crossref, Medline, Google Scholar
5 Papaspyridonos M, McNeill E, de Bono JP et al.. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008; 28(3):433–440. https://doi.org/10.1161/ATVBAHA.107.159160 Crossref, Medline, Google Scholar
6 Anand IS, Rector TS, Kuskowski M et al.. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013; 15(5):511–518. https://doi.org/10.1093/eurjhf/hfs205 Crossref, Medline, Google Scholar
7 Calvier L, Miana M, Reboul P et al.. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013; 33(1):67–75. https://doi.org/10.1161/ATVBAHA.112.300569 Crossref, Medline, Google Scholar
8 Wesley UV, Vemuganti R, Ayvaci ER, Dempsey RJ. Galectin-3 enhances angiogenic and migratory potential of microglial cells via modulation of integrin linked kinase signaling. Brain Res 2013; 1496:1–9. https://doi.org/10.1016/j.brainres.2012.12.008 Crossref, Medline, Google Scholar
9 de Boer RA, van Veldhuisen DJ, Gansevoort RT et al.. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med 2012; 272(1):55–64. https://doi.org/10.1111/j.1365-2796.2011.02476.x Crossref, Medline, Google Scholar
10 Pugliese G, Iacobini C, Pesce CM, Menini S. Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology 2015; 25(2):136-50. https://doi.org/10.1093/glycob/cwu111 Crossref, Medline, Google Scholar
11 Pugliese G, Iacobini C, Ricci C et al.. Galectin-3 in diabetic patients. Clinical Chemistry and Laboratory Medicine (CCLM) 2014; 52(10):1413–1423. https://doi.org/10.1515/cclm-2014-0187 Crossref, Google Scholar
12 World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Bull World Health Organ. 2001; 79(4):373–374 Medline, Google Scholar
13 Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet 2005; 366(9498):1719–1724. https://doi.org/10.1016/S0140-6736(05)67698-2 Crossref, Medline, Google Scholar
14 Oyenihi AB, Ayeleso AO, Mukwevho E, Masola B. Antioxidant strategies in the management of diabetic neuropathy. BioMed Res Int 2015; 2015:1–15. https://doi.org/10.1155/2015/515042 Crossref, Google Scholar
15 Madrigal-Matute J, Lindholt JS, Fernandez-Garcia CE et al.. Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis. J Am Heart Assoc 2014; 3(4):e000785. https://doi.org/10.1161/JAHA.114.000785 Crossref, Medline, Google Scholar
16 Nachtigal M, Al-Assaad Z, Mayer EP et al.. Galectin-3 expression in human atherosclerotic lesions. Am J Pathol 1998; 152(5):1199–1208 Medline, Google Scholar
17 Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 2008; 172(1):247–255. https://doi.org/10.2353/ajpath.2008.070348 Crossref, Medline, Google Scholar
18 Martínez-Martínez E, López-Ándres N, Jurado-López R et al.. Galectin-3 participates in cardiovascular remodeling associated with obesity novelty and significance. Hypertension 2015; 66(5):961–969. https://doi.org/10.1161/HYPERTENSIONAHA.115.06032 Crossref, Medline, Google Scholar
19 Martínez-Martínez E, Jurado-López R, Valero-Muñoz M et al.. Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress. J Hypertens 2014; 32(5):1104–1114. https://doi.org/10.1097/HJH.0000000000000149 Crossref, Medline, Google Scholar
20 de Boer RA, Edelmann F, Cohen-Solal A et al.. Galectin-3 in heart failure with preserved ejection fraction. Eur J Heart Fail 2013; 15(10):1095–1101. https://doi.org/10.1093/eurjhf/hft077 Crossref, Medline, Google Scholar
21 Menini S, Iacobini C, Ricci C et al.. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc Res 2013; 100(3):472–480. https://doi.org/10.1093/cvr/cvt206 Crossref, Medline, Google Scholar
22 Jin QH, Lou YF, Li TL et al.. Serum galectin-3: a risk factor for vascular complications in type 2 diabetes mellitus. Chin Med J (Engl) 2013; 126(11):2109–2115 Medline, Google Scholar
23 Papaspyridonos M, McNeill E, de Bono JP et al.. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008; 28(3):433–440. https://doi.org/10.1161/ATVBAHA.107.159160 Crossref, Medline, Google Scholar
24 Karlsson A, Christenson K, Matlak M et al.. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology 2008; 19(1):16–20. https://doi.org/10.1093/glycob/cwn104 Crossref, Medline, Google Scholar
25 Fukumori T, Takenaka Y, Yoshii T et al.. CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res 2003; 63(23):8302–8311 Medline, Google Scholar
26 Henderson NC, Mackinnon AC, Farnworth SL et al.. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172(2):288–298. https://doi.org/10.2353/ajpath.2008.070726 Crossref, Medline, Google Scholar
27 Tony EA, El Deen Mohammed HS, Fathi N. Serum and urinary biomarkers endothelin-1, beta-2 microglobulin, cystatin c, galectin-3 and alpha-1-acid glycoprotein; can they surrogate clinical and histological staging in lupus nephritis patients? J Arthritis 2016; 05(06):223. https://doi.org/10.4172/2167-7921.1000223 Crossref, Google Scholar
28 Sármán B, Tóth M, Somogyi A. Role of endothelin-1 in diabetes mellitus. Diabetes Metab Rev 1998; 14(2):171–175. https://doi.org/10.1002/(SICI)1099-0895(199806)14:2<171::AID-DMR207>3.0.CO;2-G Crossref, Medline, Google Scholar
29 Perfetto F, Tarquini R, Tapparini L, Tarquini B. Influence of non-insulin-dependent diabetes mellitus on plasma endothelin-1 levels in patients with advanced atherosclerosis. J Diabetes Complications 1998; 12(4):187–192. https://doi.org/10.1016/S1056-8727(97)00092-5 Crossref, Medline, Google Scholar
30 Markowska AI, Liu FT, Panjwani N. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med 2010; 207(9):1981–1993. https://doi.org/10.1084/jem.20090121 Crossref, Medline, Google Scholar
31 Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005; 366(9498):1736–1743. https://doi.org/10.1016/S0140-6736(05)67700-8 Crossref, Medline, Google Scholar
32 Jazwa A, Kucharzewska P, Leja J et al.. Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice. Genet Vaccines Ther 2010; 8(1):6. https://doi.org/10.1186/1479-0556-8-6 Crossref, Medline, Google Scholar
33 Mital S, Zhang X, Zhao G et al.. Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. Am J Physiol Heart Circ Physiol 2000; 279(6):H2649–H2657. https://doi.org/10.1152/ajpheart.2000.279.6.H2649 Crossref, Medline, Google Scholar

2 December 2018Volume 27Issue 12

ISSN (print): 0969-0700
ISSN (online): 2052-2916

Metrics

History

Published online 17 December 2018

Published in print 2 December 2018

Information

Keywords

PDF download